187 related articles for article (PubMed ID: 27477062)
1. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
[TBL] [Abstract][Full Text] [Related]
2. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
3. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
[TBL] [Abstract][Full Text] [Related]
4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
German P; Warren D; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
[TBL] [Abstract][Full Text] [Related]
6. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
8. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
9. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
10. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
[TBL] [Abstract][Full Text] [Related]
12. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
15. Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Kulkarni R; Hodder SL; Cao H; Chang S; Miller MD; White KL
HIV Clin Trials; 2017 Jul; 18(4):164-173. PubMed ID: 28891788
[TBL] [Abstract][Full Text] [Related]
16. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD
Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623
[TBL] [Abstract][Full Text] [Related]
17. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
18. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Schrijvers R; Debyser Z
Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
20. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
Imaz A; Martinez-Picado J; Niubó J; Kashuba AD; Ferrer E; Ouchi D; Sykes C; Rozas N; Acerete L; Curto J; Vila A; Podzamczer D
J Infect Dis; 2016 Nov; 214(10):1512-1519. PubMed ID: 27578849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
